Olema Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OLMA research report →
Range $20 – $30
Price Chart
About the company
Olema Pharmaceuticals, Inc. , a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc.
- CEO
- Sean Bohen
- IPO
- 2020
- Employees
- 131
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on OLMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $615.00M
- P/E
- -2.97
- PEG
- 0.15
- P/S
- 0.00
- P/B
- 1.92
- EV/EBITDA
- -2.38
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.67%
- ROIC
- -67.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-178,698,000
- Net Income
- $-162,451,000-25.5%
- EPS
- $-1.87+15.0%
- OCF Growth
- -40.6%
- FCF Growth
- -40.4%
- 52W High
- $36.26
- 52W Low
- $6.24
- 50D MA
- $7.90
- 200D MA
- $12.71
- Beta
- 2.02
- RSI (14)
- 44
- Avg Volume
- 1.27M
No earnings-call transcripts are available for OLMA yet.
- Free Float
- 80.3%
- Shares Outstanding
- 87.61M
- Float Shares
- 70.38M
of shares held by institutions
201 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 11.45M | ▼ 693.63K |
| Paradigm Biocapital Advisors LP | 8.67M | ▲ 650.00K |
| Blackrock, Inc. | 7.18M | ▲ 466.65K |
| Janus Henderson Group Ltd. | 7.11M | ▲ 398.29K |
| Jupiter Topco LLC | 7.09M | ▲ 7.09M |
| Bain Capital Life Sciences Investors, LLC | 7.09M | ▼ 387.99K |
| Bvf Inc/Il | 5.30M | 0 |
| Siren, L.L.C. | 4.86M | 0 |
| State Street Corp | 3.85M | ▼ 468.58K |
| Vanguard Group Inc | 3.56M | ▲ 364.04K |
| Vanguard Capital Management LLC | 3.51M | ▲ 171.98K |
| Logos Global Management LP | 3.21M | 0 |
Held by 267 ETFs
Biggest fund positions in OLMA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | O'Byrne Jason | other | 650,000 |
| Aug 11, 26 | O'Byrne Jason | other | 0 |
| Jul 23, 26 | Harmon Cyrus | sell | 12,500 |
| Jul 24, 26 | Harmon Cyrus | sell | 12,500 |
| Jun 18, 26 | BVF PARTNERS L P/IL | other | 29,500 |
| Jun 18, 26 | Harmon Cyrus | other | 29,500 |
| Jun 18, 26 | BUTITTA CYNTHIA M | other | 29,500 |
| Jun 18, 26 | Garland J. Scott | other | 29,500 |
| Jun 18, 26 | Hrustanovic Gorjan | other | 29,500 |
| Jun 18, 26 | CLARK IAN T | other | 29,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OLMA coverage
Recent articles, reports, and earnings notes.
No research on OLMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OLMA report →Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
globenewswire.com · Nov 18
Olema Oncology, Inc. (OLMA) Olema Pharmaceuticals, Inc. Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Olema Oncology to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 16
Olema Pharmaceuticals, Inc. (OLMA) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 12
Olema Oncology Announces Corporate Name Change
globenewswire.com · Nov 12
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Has Consensus Target Price of $40.60
defenseworld.net · Nov 11
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
globenewswire.com · Nov 10
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.